Company intelligence
Mabion S.A.
Your Biologics Partner
About Mabion S.A.
Mabion Biologics is a Poland-based biologics company specializing in the development and GMP manufacturing of large-molecule therapeutics, including monoclonal antibodies, biosimilars, recombinant proteins, and emerging complex biologics (like bispecifics or ADCs). The company provides services covering cell line development, upstream and downstream bioprocessing, analytical development, quality control, logistics, clinical and commercial manufacturing. Mabion gained international recognition through its participation in recombinant spike antigen manufacturing activities related to the Novavax COVID-19 vaccine program. Mabion is a highly specialized European Drug Substance development and manufacturing partner focused on large molecule manufacturing, biosimilar programs, innovation-driven collaborations, and strategic co-development partnerships. The company aims to become the most flexible and technologically advanced large molecule CDMO for biologics in Europe, with strategic focus areas including ADCs, bispecific antibodies, highly potent biologics, biosimilars, and innovative CD20-based projects. Mabion S.A. is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu
Verified activity
Signals from Mabion S.A.
6 published signals
Presence & Recognition
Mabion S.A. team took part in an initiative organized by the Fundacja Poland Business Run to support those most in need, including people with mobility impairments and those who have undergone limb amputations.
Reported by Mabion S.A.
Presence & Recognition
Mabion S.A. is hosting a webinar titled From Antibody to Conjugate: Guiding the ADC Development Journey featuring perspectives from Mabion S.A., KriSan Biotech Co., Ltd., and WPD Pharmaceuticals Sp. z o.o.
Reported by Mabion S.A.
Presence & Recognition
Mabion S.A. is hosting a biologics development and manufacturing program event on October 6-8 at Booth 12F33
Reported by Mabion S.A.
Presence & Recognition
Mabion S.A. announced that Jakub Knurek has been named a finalist in the Future Leader category of the CPHI Pharma Awards
Reported by Mabion S.A.
Presence & Recognition
Mabion S.A. is flying to BioJapan in Yokohama from October 7-9, 2026, to participate in the biotechnology industry matchmaking event.
Reported by Mabion S.A.
Research & Knowledge
Mabion S.A. published an article titled 'PD-1 Antibody Development Programs for Cancer Immunotherapy' detailing the story from the discovery of PD-1 through checkpoint inhibitors to emerging bispecific antibodies.
Reported by Mabion S.A.